prevent muscle loss glp 1 and GLP-1R agonists use GLP-1 & Muscle Loss: Evidence

Patent law is only one part of a much broader equation.The growing burden of diabetes across Africa provides an opportunity to rethink how intellectual property, public health and industrial policy interact before the continent faces another access crisis.The legal tools already exist.The more difficult question is whether governments are prepared to use them and whether the international community is willing to support a model of pharmaceutical innovation that rewards research while recognising that access to essential medicines is, ultimately, a matter of public interest.This is a co-published article, originally published on WIPR.

All patients with diabetes should have yearly eye exams

Scottsdale Restorative Medicine provides semiglutide injections for the treatment of overweight and obesity

By 2030, the global prevalence of obesity is expected to reach one billion

It is currently in Phase 2 clinical trials for the treatment of overweight and obesity